nr082
Gene therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jun 18, 2021 (NCT04912843)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- NADH-ubiquinone oxidoreductase chain 4Supplementation
MT-ND4 supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05293626 | Phase 1/Phase 2 (Phase 2) | May 22, 2023 | Neurophth Therapeutics Inc |
| NCT04912843 | Phase 1/Phase 2 (Phase 2) | Jun 18, 2021 | Government of China |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 1 | 1 | 1 | 2021 |
| Neurophth Therapeutics Inc | For profit | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1